{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Part 1 - Criteria generation setup sandbox"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "api key:········\n",
      "redacted\n"
     ]
    }
   ],
   "source": [
    "import openai\n",
    "import getpass\n",
    "\n",
    "api_key = getpass.getpass(\"api key:\")\n",
    "openai.api_key = api_key\n",
    "print('redacted')\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ChatCompletionMessage(content='Functions call themselves,  \\nLayers of depth intertwine,  \\nTruth in loops of code.', refusal=None, role='assistant', function_call=None, tool_calls=None)\n"
     ]
    }
   ],
   "source": [
    "# openai.api_key = api_key\n",
    "client = OpenAI(\n",
    "    api_key = api_key,\n",
    ")\n",
    "\n",
    "\n",
    "completion = client.chat.completions.create(\n",
    "    model=\"gpt-4o-mini\",\n",
    "    messages=[\n",
    "        {\"role\": \"system\", \"content\": \"You are a helpful assistant.\"},\n",
    "        {\"role\": \"user\",\n",
    "            \"content\": \"Write a haiku about recursion in programming.\"\n",
    "        }\n",
    "    ]\n",
    ")\n",
    "\n",
    "print(completion.choices[0].message)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_completion(prompt, model=\"gpt-3.5-turbo\"):\n",
    "    messages = [{\"role\": \"user\", \"content\": prompt}]\n",
    "    response = client.chat.completions.create(\n",
    "        model=model,\n",
    "        messages=messages,\n",
    "        temperature=0, # this is the degree of randomness of the model's output\n",
    "    )\n",
    "    return response.choices[0].message.content"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "To find clinical trials for patients over 18 years old with heart disease, you can use several resources:\n",
      "\n",
      "1. **ClinicalTrials.gov**: This is a database of privately and publicly funded clinical studies conducted around the world. You can search for trials by entering keywords such as \"heart disease\" and applying filters for age and other criteria.\n",
      "\n",
      "   - Go to [ClinicalTrials.gov](https://clinicaltrials.gov/)\n",
      "   - Use the search bar to enter \"heart disease.\"\n",
      "   - Use the filters to select age (e.g., \"18 years and older\").\n",
      "\n",
      "2. **World Health Organization (WHO) International Clinical Trials Registry Platform**: This platform provides access to clinical trial information from various countries.\n",
      "\n",
      "   - Visit the [WHO ICTRP](https://www.who.int/clinical-trials-registry-platform)\n",
      "   - Search for \"heart disease\" and apply relevant filters.\n",
      "\n",
      "3. **European Union Clinical Trials Register**: If you are in Europe, this site allows you to search for protocol information on interventional clinical trials conducted in the European Union member states.\n",
      "\n",
      "   - Go to [EU Clinical Trials Register](https://www.clinicaltrialsregister.eu/)\n",
      "   - Search for \"heart disease\" and filter by age.\n",
      "\n",
      "4. **Local Hospitals and Research Institutions**: Many hospitals and universities conduct their own clinical trials. Check their websites or contact their research departments for information on ongoing studies related to heart disease.\n",
      "\n",
      "5. **Patient Advocacy Groups**: Organizations such as the American Heart Association or similar groups in your country often have resources or listings of clinical trials.\n",
      "\n",
      "6. **Consult with a Healthcare Provider**: Your doctor or cardiologist may have information about ongoing clinical trials that are suitable for you or your loved one.\n",
      "\n",
      "If you need help navigating any of these resources or have specific criteria in mind (e.g., type of heart disease, location), please let me know!\n"
     ]
    }
   ],
   "source": [
    "prompt = 'find me clinical trials for patients of age > 18 yo and with heart diease'\n",
    "\n",
    "response = get_completion(prompt, 'gpt-4o-mini')\n",
    "print(response)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# !pip install openai==0.27.6"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "openai 0.27.6\r\n"
     ]
    }
   ],
   "source": [
    "!openai -V\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Part 3 - dataset generation sandbox - Test set: get some example clinical trials focusing on FHA "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "\n",
    "# https://clinicaltrials.gov/data-api/api\n",
    "API_SERVER = \"https://clinicaltrials.gov/api/v2\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 87,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'apiVersion': '2.0.3', 'dataTimestamp': '2024-08-26T11:12:53'}"
      ]
     },
     "execution_count": 87,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# test connection\n",
    "\n",
    "test_conn_endpoint = f\"{API_SERVER}/version\"\n",
    "\n",
    "\n",
    "resp_v = requests.get(test_conn_endpoint).json()\n",
    "resp_v"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 89,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'protocolSection': {'identificationModule': {'nctId': 'NCT05410886',\n",
       "   'orgStudyIdInfo': {'id': '20HH6115'},\n",
       "   'organization': {'fullName': 'Imperial College London', 'class': 'OTHER'},\n",
       "   'briefTitle': 'Screening Women for Functional Hypothalamic Amenorrhea (FHA)',\n",
       "   'officialTitle': 'A Questionnaire-based Study to Improve the Diagnosis of Functional Hypothalamic Amenorrhea (FHA) in Women With Secondary Amenorrhea Attending Hospital'},\n",
       "  'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "   'overallStatus': 'COMPLETED',\n",
       "   'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "   'startDateStruct': {'date': '2021-02-11', 'type': 'ACTUAL'},\n",
       "   'primaryCompletionDateStruct': {'date': '2024-02-02', 'type': 'ACTUAL'},\n",
       "   'completionDateStruct': {'date': '2024-02-02', 'type': 'ACTUAL'},\n",
       "   'studyFirstSubmitDate': '2022-06-06',\n",
       "   'studyFirstSubmitQcDate': '2022-06-06',\n",
       "   'studyFirstPostDateStruct': {'date': '2022-06-08', 'type': 'ACTUAL'},\n",
       "   'lastUpdateSubmitDate': '2024-04-26',\n",
       "   'lastUpdatePostDateStruct': {'date': '2024-04-29', 'type': 'ACTUAL'}},\n",
       "  'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "   'leadSponsor': {'name': 'Imperial College London', 'class': 'OTHER'},\n",
       "   'collaborators': [{'name': 'University College, London',\n",
       "     'class': 'OTHER'}]},\n",
       "  'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "   'isFdaRegulatedDevice': False},\n",
       "  'descriptionModule': {'briefSummary': \"What do the investigators know already? Many women suffer loss of periods (amenorrhoea). One of the most common causes of period loss is called 'functional hypothalamic amenorrhea' (FHA). FHA is difficult to diagnose and may be mistaken for other conditions causing period loss, such as polycystic ovarian syndrome (PCOS). This could cause delays in starting the correct treatment.\\n\\nWhat is the justification for doing this study? Undiagnosed women with FHA are predisposed to complications related to low oestrogen levels, such as osteoporosis, bone fractures and infertility. The failure to accurately identify women with FHA and mislabel those women with FHA as having PCOS, may delay appropriate treatment. Treatment delay causes harm for affected women, including bone fractures and infertility.\\n\\nWhat do the investigators propose? Improve the diagnosis of women with FHA by composing an assessment score, which could be used by women to improve the accuracy of diagnosing FHA. The investigators designed a questionnaire based on literature search, which can be used to identify women with FHA. A questionnaire-based study (on-line or in person) will be performed to identify risk of FHA, in women referred to hospital with period loss.\",\n",
       "   'detailedDescription': \"A questionnaire was developed to be used by women with period loss to facilitate the diagnosis of women with FHA. The development of the questionnaire was based on systematic literature review and comments from a small patient involvement group, as per National Institute for Health and Care Research (NIHR) INVOLVE guidelines.\\n\\nParticipants will be recruited via distributing a patient information sheet, consent form and a questionnaire to all women referred with amenorrhea to the Endocrinology or Reproductive Medicine clinics at Imperial College Healthcare NHS Trust and/or participating NHS organisations. Completion of the consent form and questionnaire is entirely dependent on each potential participant's choice.\\n\\nEvery woman taking part can complete the questionnaire before or after her appointment. All questionnaires will be anonymised with a unique study code, and handed back to the NHS clinician.\"},\n",
       "  'conditionsModule': {'conditions': ['Amenorrhea Secondary']},\n",
       "  'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "   'patientRegistry': False,\n",
       "   'designInfo': {'observationalModel': 'OTHER',\n",
       "    'timePerspective': 'PROSPECTIVE'},\n",
       "   'enrollmentInfo': {'count': 20, 'type': 'ACTUAL'}},\n",
       "  'armsInterventionsModule': {'interventions': [{'type': 'OTHER',\n",
       "     'name': 'Questionnaire',\n",
       "     'description': 'A questionnaire including up to 20 questions will be distributed to study participants. This questionnaire will be used to identify women with FHA.'}]},\n",
       "  'outcomesModule': {'primaryOutcomes': [{'measure': 'Frequency of clinical features in women with Functional hypothalamic amenorrhea',\n",
       "     'description': 'Descriptive statistics will be applied to questionnaire responses looking at frequency of different clinical features in women with FHA and women with other diagnoses.',\n",
       "     'timeFrame': '3 years'}],\n",
       "   'otherOutcomes': [{'measure': 'Frequency of biochemical features in women with Functional hypothalamic amenorrhea',\n",
       "     'description': 'Descriptive statistics will be applied to standard medical investigation results looking at frequency of different biochemical features in women with FHA and women with other diagnoses.',\n",
       "     'timeFrame': '3 years'}]},\n",
       "  'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Any woman 18-58 years of age\\n* Secondary amenorrhea defined by either menstrual cycle interval persistently exceeding 45 days and/or those with period loss for 3 months or more\\n\\nExclusion Criteria:\\n\\n* Women who never had periods (primary amenorrhea).',\n",
       "   'healthyVolunteers': False,\n",
       "   'sex': 'FEMALE',\n",
       "   'minimumAge': '18 Years',\n",
       "   'maximumAge': '58 Years',\n",
       "   'stdAges': ['ADULT'],\n",
       "   'studyPopulation': 'All women referred by their GP with amenorrhea to the Endocrinology or Reproductive Medicine clinics at Imperial College Healthcare NHS Trust hospitals and participating NHS organisations.',\n",
       "   'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "  'contactsLocationsModule': {'overallOfficials': [{'name': 'Channa Jayasean, PhD',\n",
       "     'affiliation': 'Imperial College London',\n",
       "     'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "   'locations': [{'facility': 'University College London Hospital NHS Trust',\n",
       "     'city': 'London',\n",
       "     'zip': 'NW1 2BU',\n",
       "     'country': 'United Kingdom',\n",
       "     'geoPoint': {'lat': 51.50853, 'lon': -0.12574}},\n",
       "    {'facility': 'Imperial College Healthcare NHS Trust',\n",
       "     'city': 'London',\n",
       "     'zip': 'W12 0HS',\n",
       "     'country': 'United Kingdom',\n",
       "     'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}]},\n",
       "  'referencesModule': {'references': [{'pmid': '33354766',\n",
       "     'type': 'BACKGROUND',\n",
       "     'citation': 'Phylactou M, Clarke SA, Patel B, Baggaley C, Jayasena CN, Kelsey TW, Comninos AN, Dhillo WS, Abbara A. Clinical and biochemical discriminants between functional hypothalamic amenorrhoea (FHA) and polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2021 Aug;95(2):239-252. doi: 10.1111/cen.14402. Epub 2021 Jan 19.'},\n",
       "    {'pmid': '34323305',\n",
       "     'type': 'RESULT',\n",
       "     'citation': 'Abou Sherif S, Newman R, Haboosh S, Al-Sharefi A, Papanikolaou N, Dimakopoulou A, Webber LJ, Abbara A, Franks S, Dhillo WS, Jayasena CN. Investigating the potential of clinical and biochemical markers to differentiate between functional hypothalamic amenorrhoea and polycystic ovarian syndrome: A retrospective observational study. Clin Endocrinol (Oxf). 2021 Oct;95(4):618-627. doi: 10.1111/cen.14571. Epub 2021 Aug 9.'}]}},\n",
       " 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-08-26'},\n",
       "  'conditionBrowseModule': {'meshes': [{'id': 'D000009362',\n",
       "     'term': 'Neoplasm Metastasis'},\n",
       "    {'id': 'D000000568', 'term': 'Amenorrhea'}],\n",
       "   'ancestors': [{'id': 'D000009385', 'term': 'Neoplastic Processes'},\n",
       "    {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "    {'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "    {'id': 'D000008599', 'term': 'Menstruation Disturbances'}],\n",
       "   'browseLeaves': [{'id': 'M12307',\n",
       "     'name': 'Neoplasm Metastasis',\n",
       "     'asFound': 'Secondary',\n",
       "     'relevance': 'HIGH'},\n",
       "    {'id': 'M3909',\n",
       "     'name': 'Amenorrhea',\n",
       "     'asFound': 'Amenorrhea',\n",
       "     'relevance': 'HIGH'},\n",
       "    {'id': 'M12330', 'name': 'Neoplastic Processes', 'relevance': 'LOW'},\n",
       "    {'id': 'M11582', 'name': 'Menstruation Disturbances', 'relevance': 'LOW'}],\n",
       "   'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "    {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "    {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       " 'hasResults': False}"
      ]
     },
     "execution_count": 89,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# test get by nctid NCT05410886\n",
    "\n",
    "nctId = 'NCT05410886'\n",
    "get_by_id_endpoint = f\"{API_SERVER}/studies/{nctId}\"\n",
    "\n",
    "\n",
    "resp_id= requests.get(get_by_id_endpoint).json()\n",
    "resp_id"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'studies': [{'protocolSection': {'identificationModule': {'nctId': 'NCT06533865',\n",
       "     'orgStudyIdInfo': {'id': '2024P000273'},\n",
       "     'organization': {'fullName': 'Massachusetts General Hospital',\n",
       "      'class': 'OTHER'},\n",
       "     'briefTitle': 'Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea',\n",
       "     'officialTitle': 'Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Adolescents and Young Adults With Functional Hypothalamic Amenorrhea'},\n",
       "    'statusModule': {'statusVerifiedDate': '2024-08',\n",
       "     'overallStatus': 'NOT_YET_RECRUITING',\n",
       "     'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "     'startDateStruct': {'date': '2024-10-01', 'type': 'ESTIMATED'},\n",
       "     'primaryCompletionDateStruct': {'date': '2028-12-01',\n",
       "      'type': 'ESTIMATED'},\n",
       "     'completionDateStruct': {'date': '2029-06-01', 'type': 'ESTIMATED'},\n",
       "     'studyFirstSubmitDate': '2024-07-30',\n",
       "     'studyFirstSubmitQcDate': '2024-07-30',\n",
       "     'studyFirstPostDateStruct': {'date': '2024-08-01', 'type': 'ACTUAL'},\n",
       "     'lastUpdateSubmitDate': '2024-08-04',\n",
       "     'lastUpdatePostDateStruct': {'date': '2024-08-06', 'type': 'ACTUAL'}},\n",
       "    'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "      'investigatorFullName': 'Karen Klahr Miller, MD',\n",
       "      'investigatorTitle': 'Chief, Neuroendocrine Unit, Massachusetts General Hospital',\n",
       "      'investigatorAffiliation': 'Massachusetts General Hospital'},\n",
       "     'leadSponsor': {'name': 'Massachusetts General Hospital',\n",
       "      'class': 'OTHER'}},\n",
       "    'oversightModule': {'oversightHasDmc': True,\n",
       "     'isFdaRegulatedDrug': True,\n",
       "     'isFdaRegulatedDevice': False},\n",
       "    'descriptionModule': {'briefSummary': 'The goal of this study is to determine whether romosozumab will improve bone density in girls and women with functional hypothalamic amenorrhea (cessation of the menstrual period due to intense exercise, stress, or an eating disorder) who have low bone density. Participants will be randomly assigned to receive romosozumab or placebo for 6 months. All participants will receive one IV infusion of zoledronate at the 6 month visit. All participants will also receive transdermal estradiol and cyclic progesterone. We will investigate whether participants who receive active romosozumab will demonstrate greater improvements in bone density at one year than those who receive placebo. We will also compare bone density over a year with healthy controls (girls and women of similar age who have regular menstrual periods).'},\n",
       "    'conditionsModule': {'conditions': ['FHA (Functional Hypothalamic Amenorrhea)']},\n",
       "    'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "     'phases': ['PHASE3'],\n",
       "     'designInfo': {'allocation': 'RANDOMIZED',\n",
       "      'interventionModel': 'PARALLEL',\n",
       "      'primaryPurpose': 'TREATMENT',\n",
       "      'maskingInfo': {'masking': 'TRIPLE',\n",
       "       'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}},\n",
       "     'enrollmentInfo': {'count': 114, 'type': 'ESTIMATED'}},\n",
       "    'armsInterventionsModule': {'armGroups': [{'label': 'Romosozumab',\n",
       "       'type': 'EXPERIMENTAL',\n",
       "       'description': 'Participants with functional hypothalamic amenorrhea randomized to romosozumab.',\n",
       "       'interventionNames': ['Drug: Romosozumab', 'Drug: Zoledronic acid']},\n",
       "      {'label': 'Placebo',\n",
       "       'type': 'PLACEBO_COMPARATOR',\n",
       "       'description': 'Participants with functional hypothalamic amenorrhea randomized to placebo.',\n",
       "       'interventionNames': ['Drug: Placebo', 'Drug: Zoledronic acid']},\n",
       "      {'label': 'Healthy Controls',\n",
       "       'type': 'NO_INTERVENTION',\n",
       "       'description': 'Healthy controls (girls and women with regular menstrual periods) will be followed without intervention.'}],\n",
       "     'interventions': [{'type': 'DRUG',\n",
       "       'name': 'Romosozumab',\n",
       "       'description': 'Six monthly subcutaneous injections. This group will also receive a 100-microgram transdermal estradiol patch applied twice weekly, and 200 mg of oral progesterone for the first 12 days of each month.',\n",
       "       'armGroupLabels': ['Romosozumab'],\n",
       "       'otherNames': ['Evenity']},\n",
       "      {'type': 'DRUG',\n",
       "       'name': 'Placebo',\n",
       "       'description': 'Identical to romosozumab but inactive. This group will also receive a 100-microgram transdermal estradiol patch applied twice weekly, and 200 mg of oral progesterone for the first 12 days of each month.',\n",
       "       'armGroupLabels': ['Placebo']},\n",
       "      {'type': 'DRUG',\n",
       "       'name': 'Zoledronic acid',\n",
       "       'description': 'One intravenous infusion',\n",
       "       'armGroupLabels': ['Placebo', 'Romosozumab'],\n",
       "       'otherNames': ['Zoledronate, Reclast']}]},\n",
       "    'outcomesModule': {'primaryOutcomes': [{'measure': 'Lumbar spine bone density',\n",
       "       'description': '6-month change in lumbar spine bone density',\n",
       "       'timeFrame': '0 and 6 months'},\n",
       "      {'measure': 'Tibial cortical thickness',\n",
       "       'description': '6-month change in tibial cortical thickness',\n",
       "       'timeFrame': '0 and 6 months'},\n",
       "      {'measure': 'Tibial failure load',\n",
       "       'description': '6-month change in tibial failure load',\n",
       "       'timeFrame': '0 and 6 months'}],\n",
       "     'secondaryOutcomes': [{'measure': 'Femoral neck and total hip bone density',\n",
       "       'description': '6- and 12-month change in femoral neck and total hip bone density',\n",
       "       'timeFrame': '0, 6, and 12 months'},\n",
       "      {'measure': 'Lumbar spine bone density',\n",
       "       'description': '12-month change in lumbar spine bone density',\n",
       "       'timeFrame': '0 and 12 months'},\n",
       "      {'measure': 'Radial cortical thickness',\n",
       "       'description': '6- and 12-month change in radial cortical thickness',\n",
       "       'timeFrame': '0, 6, and 12 months'},\n",
       "      {'measure': 'Tibial cortical thickness',\n",
       "       'description': '12-month change in tibial cortical thickness',\n",
       "       'timeFrame': '0 and 12 months'},\n",
       "      {'measure': 'P1NP and CTX',\n",
       "       'description': '1-, 6-, and 12-month change in P1NP and CTX',\n",
       "       'timeFrame': '0, 1, 6, and 12 months'},\n",
       "      {'measure': 'Radial failure load',\n",
       "       'description': '6- and 12-month change in radial failure load',\n",
       "       'timeFrame': '0, 6, and 12 months'},\n",
       "      {'measure': 'Tibial failure load',\n",
       "       'description': '12-month change in change in tibial failure load',\n",
       "       'timeFrame': '0 and 12 months'},\n",
       "      {'measure': 'Lumbar spine, femoral neck, and total hip bone density',\n",
       "       'description': '6- and 12-month in lumbar spine, femoral neck, and total hip bone density',\n",
       "       'timeFrame': '0, 6, and 12 months'},\n",
       "      {'measure': 'P1NP and CTX',\n",
       "       'description': '1-, 6- and 12-month change in markers of bone metabolism',\n",
       "       'timeFrame': '0, 1, 6 and 12 months'},\n",
       "      {'measure': 'Tibial and radial cortical thickness',\n",
       "       'description': '6- and 12-month change in tibial and radial cortical thickness',\n",
       "       'timeFrame': '0, 6 and 12 months'},\n",
       "      {'measure': 'Tibial and radial failure load',\n",
       "       'description': '6- and 12-month change in tibial and radial failure load',\n",
       "       'timeFrame': '0, 6 and 12 months'}]},\n",
       "    'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\nFor functional hypothalamic amenorrhea and controls:\\n\\n* Female, age 14-25 years, skeletally mature with bone age ≥ 14 years (only 2% of growth left)\\n* For women of reproductive age, agree to use an effective non-hormonal contraceptive method or a progestin releasing intrauterine device (no evidence of systemic skeletal effects) for the study duration\\n* Negative βHCG (pregnancy test)\\n* TSH, prolactin, potassium, magnesium within the normal range\\n* Serum ALT ≤ 3 times upper limit of normal, LDL ≤ 190 mg/dl\\n* eGFR ≥ 30ml/minute\\n\\nAdditional inclusion criteria for functional hypothalamic amenorrhea:\\n\\n* Less than 3 menses in the preceding 6 months\\n* BMD Z-score \\\\< -1.0 at ≥ 1 skeletal site\\n* Dental check-up within the past year\\n\\nExclusion Criteria:\\n\\nFor functional hypothalamic amenorrhea and controls\\n\\n* Disease other than FHA known to affect bone, including untreated thyroid dysfunction, Cushing's disease, renal failure, diabetes mellitus\\n* Use of bisphosphonates\\n* Use of other medications known to affect bone metabolism within 3 months of the study (other than calcium and vitamin D supplementation).\\n* Substance abuse disorder; current smoker\\n* History of malignancy or Paget disease of bone\\n* Pregnant, planning to become pregnant within 12 months after the end of treatment and/or breastfeeding\\n\\nAdditional exclusion criteria for functional hypothalamic amenorrhea\\n\\n* Cardiovascular: Myocardial infarction or stroke; history of hypertension or use of anti-hypertensive medications\\n* Immunodeficiency or taking immunosuppressive therapy\\n* Other conditions that can cause oligo-amenorrhea such as PCOS, premature ovarian insufficiency\\n* Dental: Osteonecrosis of the jaw (ONJ) or risk factor for ONJ, such as invasive dental procedures (tooth extraction, dental implants, oral surgery in the past 3 months), poor oral hygiene, periodontal and/or pre-existing dental disease, and current use of corticosteroids\\n* Planned invasive dental procedure over the next 12 months (the duration of the study)\\n* Known sensitivity or absolute contraindication to any of the products or components of the medications to be administered (romosozumab, zoledronic acid, transdermal estradiol, micronized progesterone, calcium or vitamin D supplements)\\n\\nAdditional exclusion criteria for normal-weight healthy controls\\n\\n• BMD Z-score \\\\<-2.5 (who we will refer for evaluation)\",\n",
       "     'healthyVolunteers': True,\n",
       "     'sex': 'FEMALE',\n",
       "     'minimumAge': '14 Years',\n",
       "     'maximumAge': '25 Years',\n",
       "     'stdAges': ['CHILD', 'ADULT']}},\n",
       "   'derivedSection': {'miscInfoModule': {'versionHolder': '2024-08-26'},\n",
       "    'conditionBrowseModule': {'meshes': [{'id': 'D000000568',\n",
       "       'term': 'Amenorrhea'}],\n",
       "     'ancestors': [{'id': 'D000008599', 'term': 'Menstruation Disturbances'},\n",
       "      {'id': 'D000010335', 'term': 'Pathologic Processes'}],\n",
       "     'browseLeaves': [{'id': 'M3909',\n",
       "       'name': 'Amenorrhea',\n",
       "       'asFound': 'Amenorrhea',\n",
       "       'relevance': 'HIGH'},\n",
       "      {'id': 'M11582',\n",
       "       'name': 'Menstruation Disturbances',\n",
       "       'relevance': 'LOW'}],\n",
       "     'browseBranches': [{'abbrev': 'BC23',\n",
       "       'name': 'Symptoms and General Pathology'},\n",
       "      {'abbrev': 'All', 'name': 'All Conditions'}]},\n",
       "    'interventionBrowseModule': {'meshes': [{'id': 'D000077211',\n",
       "       'term': 'Zoledronic Acid'}],\n",
       "     'ancestors': [{'id': 'D000050071',\n",
       "       'term': 'Bone Density Conservation Agents'},\n",
       "      {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'}],\n",
       "     'browseLeaves': [{'id': 'M266279',\n",
       "       'name': 'Estradiol 17 beta-cypionate',\n",
       "       'relevance': 'LOW'},\n",
       "      {'id': 'M266280', 'name': 'Estradiol 3-benzoate', 'relevance': 'LOW'},\n",
       "      {'id': 'M8108', 'name': 'Estradiol', 'relevance': 'LOW'},\n",
       "      {'id': 'M234941', 'name': 'Polyestradiol phosphate', 'relevance': 'LOW'},\n",
       "      {'id': 'M1699',\n",
       "       'name': 'Zoledronic Acid',\n",
       "       'asFound': 'Cortex',\n",
       "       'relevance': 'HIGH'},\n",
       "      {'id': 'M14245', 'name': 'Progesterone', 'relevance': 'LOW'},\n",
       "      {'id': 'M8116', 'name': 'Estrogens', 'relevance': 'LOW'}],\n",
       "     'browseBranches': [{'abbrev': 'Repr',\n",
       "       'name': 'Reproductive Control Agents'},\n",
       "      {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "      {'abbrev': 'BDCA', 'name': 'Bone Density Conservation Agents'}]}},\n",
       "   'hasResults': False},\n",
       "  {'protocolSection': {'identificationModule': {'nctId': 'NCT05410886',\n",
       "     'orgStudyIdInfo': {'id': '20HH6115'},\n",
       "     'organization': {'fullName': 'Imperial College London', 'class': 'OTHER'},\n",
       "     'briefTitle': 'Screening Women for Functional Hypothalamic Amenorrhea (FHA)',\n",
       "     'officialTitle': 'A Questionnaire-based Study to Improve the Diagnosis of Functional Hypothalamic Amenorrhea (FHA) in Women With Secondary Amenorrhea Attending Hospital'},\n",
       "    'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "     'overallStatus': 'COMPLETED',\n",
       "     'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "     'startDateStruct': {'date': '2021-02-11', 'type': 'ACTUAL'},\n",
       "     'primaryCompletionDateStruct': {'date': '2024-02-02', 'type': 'ACTUAL'},\n",
       "     'completionDateStruct': {'date': '2024-02-02', 'type': 'ACTUAL'},\n",
       "     'studyFirstSubmitDate': '2022-06-06',\n",
       "     'studyFirstSubmitQcDate': '2022-06-06',\n",
       "     'studyFirstPostDateStruct': {'date': '2022-06-08', 'type': 'ACTUAL'},\n",
       "     'lastUpdateSubmitDate': '2024-04-26',\n",
       "     'lastUpdatePostDateStruct': {'date': '2024-04-29', 'type': 'ACTUAL'}},\n",
       "    'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "     'leadSponsor': {'name': 'Imperial College London', 'class': 'OTHER'},\n",
       "     'collaborators': [{'name': 'University College, London',\n",
       "       'class': 'OTHER'}]},\n",
       "    'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "     'isFdaRegulatedDevice': False},\n",
       "    'descriptionModule': {'briefSummary': \"What do the investigators know already? Many women suffer loss of periods (amenorrhoea). One of the most common causes of period loss is called 'functional hypothalamic amenorrhea' (FHA). FHA is difficult to diagnose and may be mistaken for other conditions causing period loss, such as polycystic ovarian syndrome (PCOS). This could cause delays in starting the correct treatment.\\n\\nWhat is the justification for doing this study? Undiagnosed women with FHA are predisposed to complications related to low oestrogen levels, such as osteoporosis, bone fractures and infertility. The failure to accurately identify women with FHA and mislabel those women with FHA as having PCOS, may delay appropriate treatment. Treatment delay causes harm for affected women, including bone fractures and infertility.\\n\\nWhat do the investigators propose? Improve the diagnosis of women with FHA by composing an assessment score, which could be used by women to improve the accuracy of diagnosing FHA. The investigators designed a questionnaire based on literature search, which can be used to identify women with FHA. A questionnaire-based study (on-line or in person) will be performed to identify risk of FHA, in women referred to hospital with period loss.\",\n",
       "     'detailedDescription': \"A questionnaire was developed to be used by women with period loss to facilitate the diagnosis of women with FHA. The development of the questionnaire was based on systematic literature review and comments from a small patient involvement group, as per National Institute for Health and Care Research (NIHR) INVOLVE guidelines.\\n\\nParticipants will be recruited via distributing a patient information sheet, consent form and a questionnaire to all women referred with amenorrhea to the Endocrinology or Reproductive Medicine clinics at Imperial College Healthcare NHS Trust and/or participating NHS organisations. Completion of the consent form and questionnaire is entirely dependent on each potential participant's choice.\\n\\nEvery woman taking part can complete the questionnaire before or after her appointment. All questionnaires will be anonymised with a unique study code, and handed back to the NHS clinician.\"},\n",
       "    'conditionsModule': {'conditions': ['Amenorrhea Secondary']},\n",
       "    'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "     'patientRegistry': False,\n",
       "     'designInfo': {'observationalModel': 'OTHER',\n",
       "      'timePerspective': 'PROSPECTIVE'},\n",
       "     'enrollmentInfo': {'count': 20, 'type': 'ACTUAL'}},\n",
       "    'armsInterventionsModule': {'interventions': [{'type': 'OTHER',\n",
       "       'name': 'Questionnaire',\n",
       "       'description': 'A questionnaire including up to 20 questions will be distributed to study participants. This questionnaire will be used to identify women with FHA.'}]},\n",
       "    'outcomesModule': {'primaryOutcomes': [{'measure': 'Frequency of clinical features in women with Functional hypothalamic amenorrhea',\n",
       "       'description': 'Descriptive statistics will be applied to questionnaire responses looking at frequency of different clinical features in women with FHA and women with other diagnoses.',\n",
       "       'timeFrame': '3 years'}],\n",
       "     'otherOutcomes': [{'measure': 'Frequency of biochemical features in women with Functional hypothalamic amenorrhea',\n",
       "       'description': 'Descriptive statistics will be applied to standard medical investigation results looking at frequency of different biochemical features in women with FHA and women with other diagnoses.',\n",
       "       'timeFrame': '3 years'}]},\n",
       "    'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Any woman 18-58 years of age\\n* Secondary amenorrhea defined by either menstrual cycle interval persistently exceeding 45 days and/or those with period loss for 3 months or more\\n\\nExclusion Criteria:\\n\\n* Women who never had periods (primary amenorrhea).',\n",
       "     'healthyVolunteers': False,\n",
       "     'sex': 'FEMALE',\n",
       "     'minimumAge': '18 Years',\n",
       "     'maximumAge': '58 Years',\n",
       "     'stdAges': ['ADULT'],\n",
       "     'studyPopulation': 'All women referred by their GP with amenorrhea to the Endocrinology or Reproductive Medicine clinics at Imperial College Healthcare NHS Trust hospitals and participating NHS organisations.',\n",
       "     'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "    'contactsLocationsModule': {'overallOfficials': [{'name': 'Channa Jayasean, PhD',\n",
       "       'affiliation': 'Imperial College London',\n",
       "       'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "     'locations': [{'facility': 'University College London Hospital NHS Trust',\n",
       "       'city': 'London',\n",
       "       'zip': 'NW1 2BU',\n",
       "       'country': 'United Kingdom',\n",
       "       'geoPoint': {'lat': 51.50853, 'lon': -0.12574}},\n",
       "      {'facility': 'Imperial College Healthcare NHS Trust',\n",
       "       'city': 'London',\n",
       "       'zip': 'W12 0HS',\n",
       "       'country': 'United Kingdom',\n",
       "       'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}]},\n",
       "    'referencesModule': {'references': [{'pmid': '33354766',\n",
       "       'type': 'BACKGROUND',\n",
       "       'citation': 'Phylactou M, Clarke SA, Patel B, Baggaley C, Jayasena CN, Kelsey TW, Comninos AN, Dhillo WS, Abbara A. Clinical and biochemical discriminants between functional hypothalamic amenorrhoea (FHA) and polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2021 Aug;95(2):239-252. doi: 10.1111/cen.14402. Epub 2021 Jan 19.'},\n",
       "      {'pmid': '34323305',\n",
       "       'type': 'RESULT',\n",
       "       'citation': 'Abou Sherif S, Newman R, Haboosh S, Al-Sharefi A, Papanikolaou N, Dimakopoulou A, Webber LJ, Abbara A, Franks S, Dhillo WS, Jayasena CN. Investigating the potential of clinical and biochemical markers to differentiate between functional hypothalamic amenorrhoea and polycystic ovarian syndrome: A retrospective observational study. Clin Endocrinol (Oxf). 2021 Oct;95(4):618-627. doi: 10.1111/cen.14571. Epub 2021 Aug 9.'}]}},\n",
       "   'derivedSection': {'miscInfoModule': {'versionHolder': '2024-08-26'},\n",
       "    'conditionBrowseModule': {'meshes': [{'id': 'D000009362',\n",
       "       'term': 'Neoplasm Metastasis'},\n",
       "      {'id': 'D000000568', 'term': 'Amenorrhea'}],\n",
       "     'ancestors': [{'id': 'D000009385', 'term': 'Neoplastic Processes'},\n",
       "      {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "      {'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "      {'id': 'D000008599', 'term': 'Menstruation Disturbances'}],\n",
       "     'browseLeaves': [{'id': 'M12307',\n",
       "       'name': 'Neoplasm Metastasis',\n",
       "       'asFound': 'Secondary',\n",
       "       'relevance': 'HIGH'},\n",
       "      {'id': 'M3909',\n",
       "       'name': 'Amenorrhea',\n",
       "       'asFound': 'Amenorrhea',\n",
       "       'relevance': 'HIGH'},\n",
       "      {'id': 'M12330', 'name': 'Neoplastic Processes', 'relevance': 'LOW'},\n",
       "      {'id': 'M11582',\n",
       "       'name': 'Menstruation Disturbances',\n",
       "       'relevance': 'LOW'}],\n",
       "     'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "      {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "      {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "   'hasResults': False},\n",
       "  {'protocolSection': {'identificationModule': {'nctId': 'NCT00453219',\n",
       "     'orgStudyIdInfo': {'id': 'IRB00024918'},\n",
       "     'organization': {'fullName': 'Emory University', 'class': 'OTHER'},\n",
       "     'briefTitle': 'FHA: Characterization of Metabolic Status, Brain Circuitry, and Stress-Reactivity',\n",
       "     'officialTitle': 'Functional Hypothalamic Amenorrhea: Characterization of Metabolic Status, Brain Circuitry, and Stress-reactivity'},\n",
       "    'statusModule': {'statusVerifiedDate': '2013-10',\n",
       "     'overallStatus': 'WITHDRAWN',\n",
       "     'whyStopped': 'prior to participant recruitment, PI left Emory, study stopped',\n",
       "     'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "     'startDateStruct': {'date': '2011-07'},\n",
       "     'studyFirstSubmitDate': '2007-03-26',\n",
       "     'studyFirstSubmitQcDate': '2007-03-27',\n",
       "     'studyFirstPostDateStruct': {'date': '2007-03-28', 'type': 'ESTIMATED'},\n",
       "     'lastUpdateSubmitDate': '2013-10-29',\n",
       "     'lastUpdatePostDateStruct': {'date': '2013-10-30', 'type': 'ESTIMATED'}},\n",
       "    'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "     'leadSponsor': {'name': 'Emory University', 'class': 'OTHER'}},\n",
       "    'oversightModule': {'oversightHasDmc': True},\n",
       "    'descriptionModule': {'briefSummary': 'Functional Hypothalamic Amenorrhea (FHA), the spontaneous cessation of the menstrual cycle for at least 6 months after menstrual cyclicity has been established, is a common and reversible form of anovulation not due to discernible organic causes. Whereas animal studies suggest an interaction of metabolic and psychosocial stress in the genesis of FHA, the distinct central mechanisms in humans are not clear. On a behavioral level, FHA appears to depend on a complex interplay between individual stress susceptibility, stressful life events, and enduring metabolic challenge due to inappropriate attitudes towards eating and body image. We will use a comparison group of ovulatory, eumenorrheic women (EW) and a contrast group of lean women with polycystic ovary syndrome (PCOS). Although women with FHA and PCOS present with anovulation, each condition differs markedly in pathobiology (and health burden). Contrasting women with FHA to those with PCOS will afford an opportunity to understand more about the interaction between metabolism, stress, and reproduction and to determine the extent to which differences between FHA and EW are attributable to reproductive compromise (anovulation) per se versus specific to the pathogenesis of FHA or PCOS. We have used this approach to great advantage in the past to show that hypercortisolemia was confined to FHA and not PCOS (Berga 1997) and that dysfunctional (unrealistic) attitudes and decreased coping skills were reported more often in FHA than in PCOS and more in PCOS than EW. Further, this approach of comparing 3 groups will allow us to improve therapeutic approaches for two principle causes of anovulatory infertility in women. To accomplish this, we will study women with FHA, PCOS, and normal ovulatory women. The study will take place over 2 months and women will make 4-5 outpatient visits to the Clinical Integration Network Center and will have one overnight stay for frequent blood sampling.'},\n",
       "    'conditionsModule': {'conditions': ['Anovulation',\n",
       "      'FHA',\n",
       "      'Eumenorrhea',\n",
       "      'Polycystic Ovary Syndrome']},\n",
       "    'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "     'patientRegistry': False,\n",
       "     'designInfo': {'timePerspective': 'PROSPECTIVE'},\n",
       "     'bioSpec': {'retention': 'SAMPLES_WITH_DNA',\n",
       "      'description': 'Blood samples will be collected, processed, and stored for the evaluation of genetic markers assocaited with stress vulnerability. Serum and plasma specimens will be collected and stored for the evaluation of factors associated with the regulation of reproduction.'},\n",
       "     'enrollmentInfo': {'count': 0, 'type': 'ACTUAL'}},\n",
       "    'armsInterventionsModule': {'armGroups': [{'label': '1',\n",
       "       'description': 'Women ages 18-35 years with regular ovulatory menstrual cycles',\n",
       "       'interventionNames': ['Procedure: Screening evaluation',\n",
       "        'Procedure: Meal Response',\n",
       "        'Genetic: Blood Collection',\n",
       "        'Procedure: Functional MRI',\n",
       "        'Procedure: Endocrine Assessment']},\n",
       "      {'label': '2',\n",
       "       'description': 'Women ages 18-35 years with irregular or absent menstrual periods due to functional hypothalamic amenorrhea (FHA) also called stress-induced anovulation',\n",
       "       'interventionNames': ['Procedure: Screening evaluation',\n",
       "        'Procedure: Meal Response',\n",
       "        'Genetic: Blood Collection',\n",
       "        'Procedure: Functional MRI',\n",
       "        'Procedure: Endocrine Assessment']},\n",
       "      {'label': '3',\n",
       "       'description': 'Women ages 18-35 years with irregular or absent menstrual periods due to polycystic ovary syndrome(PCOS).',\n",
       "       'interventionNames': ['Procedure: Screening evaluation',\n",
       "        'Procedure: Meal Response',\n",
       "        'Genetic: Blood Collection',\n",
       "        'Procedure: Functional MRI',\n",
       "        'Procedure: Endocrine Assessment']}],\n",
       "     'interventions': [{'type': 'PROCEDURE',\n",
       "       'name': 'Screening evaluation',\n",
       "       'description': 'A detailed history will be taken and a physical examination performed along with a blood sample to verify ovulatory status in women with regular cycles and determine cause of anovulation in women with irregular or absent menstrual cycles.',\n",
       "       'armGroupLabels': ['1', '2', '3']},\n",
       "      {'type': 'PROCEDURE',\n",
       "       'name': 'Meal Response',\n",
       "       'description': 'The investigators are interested in how nutrition and metabolism can influence reproduction and they will look at how the body senses hunger and how it responses to food. Blood samples will be collected and questionnaires given to assess responses and feeling about hunger and food.',\n",
       "       'armGroupLabels': ['1', '2', '3']},\n",
       "      {'type': 'GENETIC',\n",
       "       'name': 'Blood Collection',\n",
       "       'description': 'A blood sample will be collected and used to check for genetic markers of stress vulnerability.',\n",
       "       'armGroupLabels': ['1', '2', '3']},\n",
       "      {'type': 'PROCEDURE',\n",
       "       'name': 'Functional MRI',\n",
       "       'description': 'research participants will have an functional MRI scan of their brain while reviewing word lists associated with body image and emotions. This procedure will last about 1 hour.',\n",
       "       'armGroupLabels': ['1', '2', '3']},\n",
       "      {'type': 'PROCEDURE',\n",
       "       'name': 'Endocrine Assessment',\n",
       "       'description': 'research participants will have a 30 hour inpatient hospital admission with every 15 minute blood sampling for 24 hours. Hormone measures of stress, reproduction, and appetite will be obtained.',\n",
       "       'armGroupLabels': ['1', '2', '3']}]},\n",
       "    'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Inclusion criteria for participation are a gynecological age (age since menarche) \\\\> 5 and \\\\< 25 years, and chronological age \\\\> 18 years, within 90-110% of ideal body weight as determined by the 1983 Metropolitan height and weight table for women, and exercise \\\\< 10 h/wk and run \\\\< 10 mi/wk, day-awake/night-asleep schedule.\\n* Women in the FHA and PCOS groups have to fulfill the diagnostic criteria of FHA or PCOS and to have all other causes of amenorrhea and anovulation excluded.\\n\\nExclusion Criteria:\\n\\n* Exclusion criteria are smoking, medications, including psychotropic or illicit drugs, medical, neurological, or ophthalmologic disease except acuity problems, a weight loss or gain of \\\\> 10 lb within a year preceding or since the onset of amenorrhea, a major Axis I disorder other than depression, parturition in the last 12 months and/or lactating in the last 6 months.',\n",
       "     'healthyVolunteers': True,\n",
       "     'sex': 'FEMALE',\n",
       "     'minimumAge': '18 Years',\n",
       "     'maximumAge': '35 Years',\n",
       "     'stdAges': ['ADULT'],\n",
       "     'studyPopulation': 'Women ages 18-35',\n",
       "     'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "    'contactsLocationsModule': {'overallOfficials': [{'name': 'Sarah L Berga, MD',\n",
       "       'affiliation': 'Emory University',\n",
       "       'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "     'locations': [{'facility': 'Emory University',\n",
       "       'city': 'Atlanta',\n",
       "       'state': 'Georgia',\n",
       "       'zip': '30322',\n",
       "       'country': 'United States',\n",
       "       'geoPoint': {'lat': 33.749, 'lon': -84.38798}}]},\n",
       "    'referencesModule': {'references': [{'pmid': '14556820',\n",
       "       'type': 'BACKGROUND',\n",
       "       'citation': 'Berga SL, Marcus MD, Loucks TL, Hlastala S, Ringham R, Krohn MA. Recovery of ovarian activity in women with functional hypothalamic amenorrhea who were treated with cognitive behavior therapy. Fertil Steril. 2003 Oct;80(4):976-81. doi: 10.1016/s0015-0282(03)01124-5.'},\n",
       "      {'pmid': '11476778',\n",
       "       'type': 'BACKGROUND',\n",
       "       'citation': 'Marcus MD, Loucks TL, Berga SL. Psychological correlates of functional hypothalamic amenorrhea. Fertil Steril. 2001 Aug;76(2):310-6. doi: 10.1016/s0015-0282(01)01921-5.'},\n",
       "      {'pmid': '17308138',\n",
       "       'type': 'BACKGROUND',\n",
       "       'citation': 'Berga SL, Loucks TL. Use of cognitive behavior therapy for functional hypothalamic amenorrhea. Ann N Y Acad Sci. 2006 Dec;1092:114-29. doi: 10.1196/annals.1365.010.'}]}},\n",
       "   'derivedSection': {'miscInfoModule': {'versionHolder': '2024-08-26'},\n",
       "    'conditionBrowseModule': {'meshes': [{'id': 'D000011085',\n",
       "       'term': 'Polycystic Ovary Syndrome'},\n",
       "      {'id': 'D000000858', 'term': 'Anovulation'}],\n",
       "     'ancestors': [{'id': 'D000010048', 'term': 'Ovarian Cysts'},\n",
       "      {'id': 'D000003560', 'term': 'Cysts'},\n",
       "      {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "      {'id': 'D000010049', 'term': 'Ovarian Diseases'},\n",
       "      {'id': 'D000000291', 'term': 'Adnexal Diseases'},\n",
       "      {'id': 'D000005831', 'term': 'Genital Diseases, Female'},\n",
       "      {'id': 'D000052776', 'term': 'Female Urogenital Diseases'},\n",
       "      {'id': 'D000005261',\n",
       "       'term': 'Female Urogenital Diseases and Pregnancy Complications'},\n",
       "      {'id': 'D000091642', 'term': 'Urogenital Diseases'},\n",
       "      {'id': 'D000091662', 'term': 'Genital Diseases'},\n",
       "      {'id': 'D000006058', 'term': 'Gonadal Disorders'},\n",
       "      {'id': 'D000004700', 'term': 'Endocrine System Diseases'}],\n",
       "     'browseLeaves': [{'id': 'M16355', 'name': 'Syndrome', 'relevance': 'LOW'},\n",
       "      {'id': 'M13970',\n",
       "       'name': 'Polycystic Ovary Syndrome',\n",
       "       'asFound': 'Polycystic Ovary Syndrome',\n",
       "       'relevance': 'HIGH'},\n",
       "      {'id': 'M3909', 'name': 'Amenorrhea', 'relevance': 'LOW'},\n",
       "      {'id': 'M4184',\n",
       "       'name': 'Anovulation',\n",
       "       'asFound': 'Anovulation',\n",
       "       'relevance': 'HIGH'},\n",
       "      {'id': 'M6765', 'name': 'Cysts', 'relevance': 'LOW'},\n",
       "      {'id': 'M12971', 'name': 'Ovarian Cysts', 'relevance': 'LOW'},\n",
       "      {'id': 'M12972', 'name': 'Ovarian Diseases', 'relevance': 'LOW'},\n",
       "      {'id': 'M3643', 'name': 'Adnexal Diseases', 'relevance': 'LOW'},\n",
       "      {'id': 'M8943', 'name': 'Genital Diseases, Female', 'relevance': 'LOW'},\n",
       "      {'id': 'M2876', 'name': 'Genital Diseases', 'relevance': 'LOW'},\n",
       "      {'id': 'M2875', 'name': 'Urogenital Diseases', 'relevance': 'LOW'},\n",
       "      {'id': 'M27093',\n",
       "       'name': 'Female Urogenital Diseases',\n",
       "       'relevance': 'LOW'},\n",
       "      {'id': 'M14127', 'name': 'Pregnancy Complications', 'relevance': 'LOW'},\n",
       "      {'id': 'M8399',\n",
       "       'name': 'Female Urogenital Diseases and Pregnancy Complications',\n",
       "       'relevance': 'LOW'},\n",
       "      {'id': 'M9163', 'name': 'Gonadal Disorders', 'relevance': 'LOW'},\n",
       "      {'id': 'M7862',\n",
       "       'name': 'Endocrine System Diseases',\n",
       "       'relevance': 'LOW'}],\n",
       "     'browseBranches': [{'abbrev': 'BC23',\n",
       "       'name': 'Symptoms and General Pathology'},\n",
       "      {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "      {'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "      {'abbrev': 'BXS',\n",
       "       'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'},\n",
       "      {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}]},\n",
       "    'interventionBrowseModule': {'browseLeaves': [{'id': 'M9789',\n",
       "       'name': 'Hormones',\n",
       "       'relevance': 'LOW'}],\n",
       "     'browseBranches': [{'abbrev': 'All',\n",
       "       'name': 'All Drugs and Chemicals'}]}},\n",
       "   'hasResults': False},\n",
       "  {'protocolSection': {'identificationModule': {'nctId': 'NCT02697136',\n",
       "     'orgStudyIdInfo': {'id': 'CER-001-CLIN-009'},\n",
       "     'organization': {'fullName': 'Cerenis Therapeutics, SA',\n",
       "      'class': 'INDUSTRY'},\n",
       "     'briefTitle': 'CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases',\n",
       "     'officialTitle': 'Phase 3, Multicenter, Randomized, 48 Week, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate Efficacy and Safety of CER-001 on Vessel Wall Area in Patients With Genetically Defined Familial Primary Hypoalphalipoproteinemia',\n",
       "     'acronym': 'TANGO'},\n",
       "    'statusModule': {'statusVerifiedDate': '2019-02',\n",
       "     'overallStatus': 'TERMINATED',\n",
       "     'whyStopped': 'Lack of efficacy',\n",
       "     'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "     'startDateStruct': {'date': '2015-12', 'type': 'ACTUAL'},\n",
       "     'primaryCompletionDateStruct': {'date': '2018-10', 'type': 'ACTUAL'},\n",
       "     'completionDateStruct': {'date': '2018-12-21', 'type': 'ACTUAL'},\n",
       "     'studyFirstSubmitDate': '2016-02-17',\n",
       "     'studyFirstSubmitQcDate': '2016-02-26',\n",
       "     'studyFirstPostDateStruct': {'date': '2016-03-03', 'type': 'ESTIMATED'},\n",
       "     'dispFirstSubmitDate': '2019-02-06',\n",
       "     'dispFirstSubmitQcDate': '2019-02-06',\n",
       "     'dispFirstPostDateStruct': {'date': '2019-02-11', 'type': 'ACTUAL'},\n",
       "     'lastUpdateSubmitDate': '2019-02-06',\n",
       "     'lastUpdatePostDateStruct': {'date': '2019-02-11', 'type': 'ACTUAL'}},\n",
       "    'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "     'leadSponsor': {'name': 'Cerenis Therapeutics, SA', 'class': 'INDUSTRY'}},\n",
       "    'oversightModule': {'oversightHasDmc': True},\n",
       "    'descriptionModule': {'briefSummary': 'The purpose of this study is to assess the impact of 29 intravenous infusions of CER-001 vs. placebo, given at weekly (9 infusions) and biweekly (20 infusions) intervals on carotid vessel wall area as measured by 3TMRI, when administered to patients with familial primary hypoalphalipoproteinemia with proven CVD and appropriate background lipid-lowering therapy.',\n",
       "     'detailedDescription': 'Subjects will be required to have acceptable baseline 3TMRI imaging of carotid arteries. Subjects meeting all eligibility criteria will be randomized to receive CER-001 or placebo (2:1 randomization scheme). Randomized subjects will return weekly for a total of 9 infusions and then biweekly for an additional 20 infusions. 3TMRI imaging of the carotid and femoral arteries will be performed at Week 8, Week 24 (primary endpoint) and Week 48. The total study duration from randomization can range from 50 to 54 weeks for patients completing the study as designed.'},\n",
       "    'conditionsModule': {'conditions': ['Familial Hypoalphalipoproteinemia'],\n",
       "     'keywords': ['Low HDL',\n",
       "      'Low apoA-I',\n",
       "      'ABCA-1 mutations',\n",
       "      'ApoA-I mutations']},\n",
       "    'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "     'phases': ['PHASE3'],\n",
       "     'designInfo': {'allocation': 'RANDOMIZED',\n",
       "      'interventionModel': 'PARALLEL',\n",
       "      'primaryPurpose': 'TREATMENT',\n",
       "      'maskingInfo': {'masking': 'QUADRUPLE',\n",
       "       'whoMasked': ['PARTICIPANT',\n",
       "        'CARE_PROVIDER',\n",
       "        'INVESTIGATOR',\n",
       "        'OUTCOMES_ASSESSOR']}},\n",
       "     'enrollmentInfo': {'count': 30, 'type': 'ACTUAL'}},\n",
       "    'armsInterventionsModule': {'armGroups': [{'label': 'CER-001',\n",
       "       'type': 'EXPERIMENTAL',\n",
       "       'description': 'CER-001 infusion; 9 weekly infusions followed by 20 biweekly infusions',\n",
       "       'interventionNames': ['Drug: CER-001']},\n",
       "      {'label': 'Placebo',\n",
       "       'type': 'PLACEBO_COMPARATOR',\n",
       "       'description': 'Saline infusion; 9 weekly infusions followed by 20 biweekly infusions',\n",
       "       'interventionNames': ['Drug: Placebo']}],\n",
       "     'interventions': [{'type': 'DRUG',\n",
       "       'name': 'CER-001',\n",
       "       'description': 'Recombinant human apoA-I/phospholipid complexes',\n",
       "       'armGroupLabels': ['CER-001'],\n",
       "       'otherNames': ['CAS 138-3435-67-3']},\n",
       "      {'type': 'DRUG',\n",
       "       'name': 'Placebo',\n",
       "       'description': '0.9% Sodium Chloride Injection, USP',\n",
       "       'armGroupLabels': ['Placebo'],\n",
       "       'otherNames': ['Normal saline']}]},\n",
       "    'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in mmean vessel wall area (MVWA) of the carotid artery',\n",
       "       'description': 'Change from baseline to Week 24 carotid MVWA; CER-001 versus placebo; measured by 3TMRI',\n",
       "       'timeFrame': 'Baseline to Week 24'}],\n",
       "     'secondaryOutcomes': [{'measure': 'Change in mean vessel wall area (MVWA) of the carotid artery',\n",
       "       'description': 'Change from baseline to Week 8 carotid MVWA; CER-001 versus placebo; measured by 3TMRI',\n",
       "       'timeFrame': 'Baseline to Week 8'},\n",
       "      {'measure': 'Change in mean vessel wall area (MVWA) of the carotid artery',\n",
       "       'description': 'Change from baseline to Week 48 carotid MVWA; CER-001 versus placebo; measured by 3TMRI',\n",
       "       'timeFrame': 'Baseline to Week 48'},\n",
       "      {'measure': 'Change in Target to Background Ratio (TBR) of the carotid artery',\n",
       "       'description': 'Change from baseline to Week 24 in carotid TBR; CER-001 versus placebo; measured by FDG-PET',\n",
       "       'timeFrame': 'Baseline to Week 24'}],\n",
       "     'otherOutcomes': [{'measure': 'Change in femoral MVWA',\n",
       "       'description': 'Assessed by 3TMRI; change from baseline; CER-001 versus placebo',\n",
       "       'timeFrame': 'Baseline, Weeks 8, 24 and 48'}]},\n",
       "    'eligibilityModule': {'eligibilityCriteria': 'Main Inclusion Criteria:\\n\\n* Male and female patients, aged 18 and above.\\n* ApoA-I \\\\< 70 mg/dL\\n* Symptomatic or asymptomatic cardiovascular disease\\n* Diagnosis of genetically confirmed HDL-c deficiency due to defects in genes coding for ABCA1 and/or ApoA-1\\n* Stable doses of lipid lowering therapies for at least 6 weeks prior to baseline procedures\\n\\nMain Exclusion Criteria:\\n\\n* Females of childbearing potential\\n* Patients with LCAT mutations\\n* Patients who experienced recent cardiovascular or cerebrovascular events\\n* Hypertriglyceridemia (\\\\>500 mg/dL)\\n* Severe anemia (Hgb \\\\< 10 g/dL)\\n* Uncontrolled diabetes (HbA1c \\\\>10%)\\n* Congestive heart failure (NYHA class II or higher)\\n* Contraindication for MRI scanning (e.g., implanted metal objects, claustrophobia)',\n",
       "     'healthyVolunteers': False,\n",
       "     'sex': 'ALL',\n",
       "     'minimumAge': '18 Years',\n",
       "     'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "    'contactsLocationsModule': {'overallOfficials': [{'name': 'Erik SG Stroes, MD PhD',\n",
       "       'affiliation': 'Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)',\n",
       "       'role': 'STUDY_CHAIR'}],\n",
       "     'locations': [{'facility': 'Investigative Site',\n",
       "       'city': 'Salt Lake City',\n",
       "       'state': 'Utah',\n",
       "       'country': 'United States',\n",
       "       'geoPoint': {'lat': 40.76078, 'lon': -111.89105}},\n",
       "      {'facility': 'Investigative Site',\n",
       "       'city': 'La Louvière',\n",
       "       'country': 'Belgium',\n",
       "       'geoPoint': {'lat': 50.48657, 'lon': 4.18785}},\n",
       "      {'facility': 'Investigative Site',\n",
       "       'city': 'Vancouver',\n",
       "       'state': 'British Columbia',\n",
       "       'country': 'Canada',\n",
       "       'geoPoint': {'lat': 49.24966, 'lon': -123.11934}},\n",
       "      {'facility': 'Investigative Site',\n",
       "       'city': 'Halifax',\n",
       "       'state': 'Nova Scotia',\n",
       "       'country': 'Canada',\n",
       "       'geoPoint': {'lat': 44.64533, 'lon': -63.57239}},\n",
       "      {'facility': 'Investigative Site',\n",
       "       'city': 'London',\n",
       "       'state': 'Ontario',\n",
       "       'country': 'Canada',\n",
       "       'geoPoint': {'lat': 42.98339, 'lon': -81.23304}},\n",
       "      {'facility': 'Investigative Site',\n",
       "       'city': 'Chicoutimi',\n",
       "       'state': 'Quebec',\n",
       "       'country': 'Canada',\n",
       "       'geoPoint': {'lat': 48.41963, 'lon': -71.06369}},\n",
       "      {'facility': 'Investigative Site',\n",
       "       'city': 'Montreal',\n",
       "       'state': 'Quebec',\n",
       "       'country': 'Canada',\n",
       "       'geoPoint': {'lat': 45.50884, 'lon': -73.58781}},\n",
       "      {'facility': 'Investigative Site',\n",
       "       'city': 'Lille',\n",
       "       'country': 'France',\n",
       "       'geoPoint': {'lat': 50.63297, 'lon': 3.05858}},\n",
       "      {'facility': 'Investigative Site',\n",
       "       'city': 'Montpellier',\n",
       "       'country': 'France',\n",
       "       'geoPoint': {'lat': 43.61092, 'lon': 3.87723}},\n",
       "      {'facility': 'Investigative Site',\n",
       "       'city': 'Rouen',\n",
       "       'country': 'France',\n",
       "       'geoPoint': {'lat': 49.44313, 'lon': 1.09932}},\n",
       "      {'facility': 'Investigative Site',\n",
       "       'city': 'Toulouse',\n",
       "       'country': 'France',\n",
       "       'geoPoint': {'lat': 43.60426, 'lon': 1.44367}},\n",
       "      {'facility': 'Investigative Site',\n",
       "       'city': 'Jerusalem',\n",
       "       'country': 'Israel',\n",
       "       'geoPoint': {'lat': 31.76904, 'lon': 35.21633}},\n",
       "      {'facility': 'Investigative Site',\n",
       "       'city': 'Tel Aviv',\n",
       "       'country': 'Israel',\n",
       "       'geoPoint': {'lat': 32.08088, 'lon': 34.78057}},\n",
       "      {'facility': 'Investigative Site',\n",
       "       'city': 'Genoa',\n",
       "       'country': 'Italy',\n",
       "       'geoPoint': {'lat': 44.40478, 'lon': 8.94438}},\n",
       "      {'facility': 'Investigative Site',\n",
       "       'city': 'Milan',\n",
       "       'country': 'Italy',\n",
       "       'geoPoint': {'lat': 45.46427, 'lon': 9.18951}},\n",
       "      {'facility': 'Investigative Site',\n",
       "       'city': 'Pisa',\n",
       "       'country': 'Italy',\n",
       "       'geoPoint': {'lat': 43.70853, 'lon': 10.4036}},\n",
       "      {'facility': 'Investigative Site',\n",
       "       'city': 'Rome',\n",
       "       'country': 'Italy',\n",
       "       'geoPoint': {'lat': 41.89193, 'lon': 12.51133}},\n",
       "      {'facility': 'Investigative Site',\n",
       "       'city': 'Amsterdam',\n",
       "       'country': 'Netherlands',\n",
       "       'geoPoint': {'lat': 52.37403, 'lon': 4.88969}},\n",
       "      {'facility': 'Investigative Site',\n",
       "       'city': 'Utrecht',\n",
       "       'country': 'Netherlands',\n",
       "       'geoPoint': {'lat': 52.09083, 'lon': 5.12222}}]},\n",
       "    'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED',\n",
       "     'description': 'To be determined'}},\n",
       "   'derivedSection': {'miscInfoModule': {'versionHolder': '2024-08-26'},\n",
       "    'conditionBrowseModule': {'meshes': [{'id': 'D000052456',\n",
       "       'term': 'Hypoalphalipoproteinemias'}],\n",
       "     'ancestors': [{'id': 'D000007009', 'term': 'Hypolipoproteinemias'},\n",
       "      {'id': 'D000008052', 'term': 'Lipid Metabolism, Inborn Errors'},\n",
       "      {'id': 'D000008661', 'term': 'Metabolism, Inborn Errors'},\n",
       "      {'id': 'D000030342', 'term': 'Genetic Diseases, Inborn'},\n",
       "      {'id': 'D000050171', 'term': 'Dyslipidemias'},\n",
       "      {'id': 'D000052439', 'term': 'Lipid Metabolism Disorders'},\n",
       "      {'id': 'D000008659', 'term': 'Metabolic Diseases'}],\n",
       "     'browseLeaves': [{'id': 'M27030',\n",
       "       'name': 'Hypoalphalipoproteinemias',\n",
       "       'asFound': 'Hypoalphalipoproteinemia',\n",
       "       'relevance': 'HIGH'},\n",
       "      {'id': 'M10059', 'name': 'Hypolipoproteinemias', 'relevance': 'LOW'},\n",
       "      {'id': 'M11641',\n",
       "       'name': 'Metabolism, Inborn Errors',\n",
       "       'relevance': 'LOW'},\n",
       "      {'id': 'M11054',\n",
       "       'name': 'Lipid Metabolism, Inborn Errors',\n",
       "       'relevance': 'LOW'},\n",
       "      {'id': 'M23686', 'name': 'Genetic Diseases, Inborn', 'relevance': 'LOW'},\n",
       "      {'id': 'M26181', 'name': 'Dyslipidemias', 'relevance': 'LOW'},\n",
       "      {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'},\n",
       "      {'id': 'M27029',\n",
       "       'name': 'Lipid Metabolism Disorders',\n",
       "       'relevance': 'LOW'},\n",
       "      {'id': 'T2942', 'name': 'Hypolipoproteinemia', 'relevance': 'LOW'}],\n",
       "     'browseBranches': [{'abbrev': 'BC16',\n",
       "       'name': 'Diseases and Abnormalities at or Before Birth'},\n",
       "      {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'},\n",
       "      {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "      {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "   'hasResults': False},\n",
       "  {'protocolSection': {'identificationModule': {'nctId': 'NCT00870350',\n",
       "     'orgStudyIdInfo': {'id': '2008-008195-13'},\n",
       "     'organization': {'fullName': 'Swedish Institute for Infectious Disease Control',\n",
       "      'class': 'OTHER'},\n",
       "     'briefTitle': 'An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster',\n",
       "     'officialTitle': 'An Immunogenicity and Safety Study of Combined Adsorbed Tetanus, Low Dose Diphtheria and Acellular Pertussis Vaccine (Td5ap and Td1aP) Given as a School-leaving Booster to 14-15-year-old Children Primed With a Five Component Acellular Pertussis Vaccine at 3, 5 and 12 Months of Age, and a Booster Dose at 5½ Years of Age',\n",
       "     'acronym': 'Tdap Booster'},\n",
       "    'statusModule': {'statusVerifiedDate': '2009-03',\n",
       "     'overallStatus': 'UNKNOWN',\n",
       "     'lastKnownStatus': 'ACTIVE_NOT_RECRUITING',\n",
       "     'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "     'startDateStruct': {'date': '2009-04'},\n",
       "     'primaryCompletionDateStruct': {'date': '2009-10', 'type': 'ACTUAL'},\n",
       "     'completionDateStruct': {'date': '2010-06', 'type': 'ESTIMATED'},\n",
       "     'studyFirstSubmitDate': '2009-03-26',\n",
       "     'studyFirstSubmitQcDate': '2009-03-26',\n",
       "     'studyFirstPostDateStruct': {'date': '2009-03-27', 'type': 'ESTIMATED'},\n",
       "     'lastUpdateSubmitDate': '2010-06-04',\n",
       "     'lastUpdatePostDateStruct': {'date': '2010-06-07', 'type': 'ESTIMATED'}},\n",
       "    'sponsorCollaboratorsModule': {'responsibleParty': {'oldNameTitle': 'Prof. em. Leif Gothefors',\n",
       "      'oldOrganization': 'Swedish Institute for Infectious Disease Control'},\n",
       "     'leadSponsor': {'name': 'Swedish Institute for Infectious Disease Control',\n",
       "      'class': 'OTHER'},\n",
       "     'collaborators': [{'name': 'MCM Vaccines B.V.', 'class': 'INDUSTRY'},\n",
       "      {'name': 'Statens Serum Institut', 'class': 'OTHER'}]},\n",
       "    'oversightModule': {'oversightHasDmc': True},\n",
       "    'descriptionModule': {'briefSummary': 'Open-label, randomized, multi-centre study in which 400 subjects, divided into two groups, will receive Td5ap or Td1aP as a single injection. We will then describe the immune response and safety profile of the combined vaccine booster.',\n",
       "     'detailedDescription': 'The vaccines in the study are COVAXIS (Td5ap), Sanofi Pasteur Canada, and diTekiBooster (Td1aP), Statens Serum Institut, Denmark.\\n\\nThe primary objective of the study is to describe the immune response to diphtheria toxin, tetanus toxoid, pertussis toxin, filamentous haemagglutinin (FHA), fimbriae 2/3 and pertactin four weeks after immunization with Td1aP and Td5ap.\\n\\nThe secondary objectives include:\\n\\n* describing the safety of a fith dose of DTP vaccines in 14-15 year-old children by observing systemic and local adverse reactions\\n* describing pre-booster antibody levels\\n* describing pre-booster and post-booster IgG and IgA levels in saliva\\n* describing in a subpopulation the pre-booster and post-booster T cell immune responses as determined by the production of cytokines\\n* describing in a subpopulation the pre-booster and post-booster B cell immune responses as determined by the number of effector and memory B-cells\\n\\nThe sample size is 400 subjects (200 in group 1 and 200 in group 2). It will be an open-label, randomized, multi-centre study in which group 1 will receive Td5ap as a single injection and group 2 will receive Td1aP as a single injection. DTP antibodies will be measured before and 28 days (+ 14 days) after Td5ap and Td1aP vaccination. The proportion of children with positive IgG antibody response will be measured in each study arm. Sera will be tested blindly by established ELISA methods and saliva samples will be analyzed by exploratory assays. In a subpopulation cellmediated immunity will be analyzed. The safety evaluation criteria will be the percentage of subjects with adverse events describing injection-site adverse reactions, systemic adverse events, daily temperatures and serious adverse events.'},\n",
       "    'conditionsModule': {'conditions': ['Tetanus', 'Diphtheria', 'Pertussis'],\n",
       "     'keywords': ['immunogenicity',\n",
       "      'safety',\n",
       "      'tetanus',\n",
       "      'diphtheria',\n",
       "      'acellular',\n",
       "      'pertussis',\n",
       "      'vaccine',\n",
       "      'booster',\n",
       "      'adverse event',\n",
       "      'adverse reaction',\n",
       "      'DT1aP',\n",
       "      'DT5ap',\n",
       "      'FHA',\n",
       "      'fimbriae',\n",
       "      'pertactin',\n",
       "      'SMI',\n",
       "      'Smittskyddsinstitutet',\n",
       "      'Immune response and safety profile to a Tdap booster']},\n",
       "    'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "     'phases': ['PHASE4'],\n",
       "     'designInfo': {'allocation': 'RANDOMIZED',\n",
       "      'interventionModel': 'PARALLEL',\n",
       "      'primaryPurpose': 'BASIC_SCIENCE',\n",
       "      'maskingInfo': {'masking': 'NONE'}},\n",
       "     'enrollmentInfo': {'count': 400, 'type': 'ESTIMATED'}},\n",
       "    'armsInterventionsModule': {'armGroups': [{'label': 'Td5ap',\n",
       "       'type': 'ACTIVE_COMPARATOR',\n",
       "       'description': 'Group 1 receiving Td5ap as a single intramuscular injection.',\n",
       "       'interventionNames': ['Biological: Td5ap']},\n",
       "      {'label': 'Td1aP',\n",
       "       'type': 'ACTIVE_COMPARATOR',\n",
       "       'description': 'Group 2 receiving Td1aP as a single intramuscular injection',\n",
       "       'interventionNames': ['Biological: Td1aP']}],\n",
       "     'interventions': [{'type': 'BIOLOGICAL',\n",
       "       'name': 'Td5ap',\n",
       "       'description': 'Intramuscular injection of 0.5 mL Td5ap (COVAXiS) on day 1.',\n",
       "       'armGroupLabels': ['Td5ap'],\n",
       "       'otherNames': ['COVAXiS']},\n",
       "      {'type': 'BIOLOGICAL',\n",
       "       'name': 'Td1aP',\n",
       "       'description': 'Intramuscular injection of 0.5 mL Td1aP (diTekiBooster) on day 1.',\n",
       "       'armGroupLabels': ['Td1aP'],\n",
       "       'otherNames': ['diTekiBooster']}]},\n",
       "    'outcomesModule': {'primaryOutcomes': [{'measure': 'to describe in each arm the immune response to diptheria toxin, tetanus toxoid, pertussis toxin, FHA, fimbriae 2/3 and pertactin four weeks after immunization with Td1aP and Td5ap',\n",
       "       'timeFrame': '42 days'}],\n",
       "     'secondaryOutcomes': [{'measure': 'safety of a fith dose of DTP vaccines',\n",
       "       'timeFrame': '42 days'},\n",
       "      {'measure': 'pre-booster antibody levels', 'timeFrame': '42 days'},\n",
       "      {'measure': 'pre-booster and post-booster IgG and IgA levels',\n",
       "       'timeFrame': '42 days'},\n",
       "      {'measure': 'pre-booster and post-booster T cell immune responses',\n",
       "       'timeFrame': '42 days'},\n",
       "      {'measure': 'pre-booster and post-booster B cell immune responses',\n",
       "       'timeFrame': '42 days'}]},\n",
       "    'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* healthy subject\\n* 14-15 years old\\n* eligible for their school-leaving booster for DTP\\n* received a complete primary vaccination with a 5-component acellular pertussis vaccine (DT5aP-IPV-Hib) at 3, 5 and 12 months of age and vaccinated with a 5-component acellular pertussis vaccine (Td5aP-IPV or Td5aP + IPV) as a booster at 5½ years of age\\n* informed consent form signed by the subject and parent(s)/legal representative\\n* subject understand and comply with the study procedures (i.e. able to read and write Swedish)\\n* female must provide an agreement that they are either sexually continent or practice adequate contraceptive methods (intra-uterine contraceptive device (IUCD), hormonal contraceptives, condoms or other adequate barrier contraception).\\n\\nExclusion Criteria:\\n\\n* acute febrile illness or axillary temperature ≥38.0°C at the time of vaccination\\n* receipt of immunoglobulin within the previous 3 months, immunosuppression (e g evidence of impaired cell mediated immunity, receipt of immunosuppressant drugs within the previous 3 months or receipt of systemic corticosteroids given daily or on alternate days at ≥20 mg/day prednisone equivalent during \\\\>14 days within the past 30 days)\\n* receipt of a non-study vaccine in the past 30 days\\n* evolving encephalopathy not attributable to another identifiable cause within 7 days of administration of a previous dose of any vaccine\\n* booster vaccination with tetanus, low dose diphtheria and acellular pertussis vaccine since the booster vaccination at 5½ years of age\\n* previous clinical or bacteriological diagnosis of diphtheria, tetanus or pertussis\\n* hypersensitivity to any component of any of the study vaccines\\n* current participation in any other clinical trial or participation in any clinical trial in the previous month\\n* inability to adhere to the protocol, including plans to move from the area\\n* severe chronic disease\\n* family history of congenital or hereditary immunodeficiency\\n* any sever thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection\\n* any medical condition, which in the opinion of the investigator, might interfere with the evaluation of the study objectives.',\n",
       "     'healthyVolunteers': True,\n",
       "     'sex': 'ALL',\n",
       "     'minimumAge': '14 Years',\n",
       "     'maximumAge': '15 Years',\n",
       "     'stdAges': ['CHILD']},\n",
       "    'contactsLocationsModule': {'overallOfficials': [{'name': 'Leif Gothefors, Prof. em.',\n",
       "       'affiliation': 'Swedish Institute for Infectious Disease Control',\n",
       "       'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "      {'name': 'Eva Netterlid',\n",
       "       'affiliation': 'Swedish Institute for Infectious Disease Control',\n",
       "       'role': 'STUDY_DIRECTOR'}],\n",
       "     'locations': [{'facility': 'Swedish Institute for Infectious Disease Control',\n",
       "       'city': 'Lund',\n",
       "       'zip': '221 85',\n",
       "       'country': 'Sweden',\n",
       "       'geoPoint': {'lat': 55.70584, 'lon': 13.19321}}]},\n",
       "    'referencesModule': {'references': [{'pmid': '31945015',\n",
       "       'type': 'DERIVED',\n",
       "       'citation': 'Lin A, Apostolovic D, Jahnmatz M, Liang F, Ols S, Tecleab T, Wu C, van Hage M, Solovay K, Rubin K, Locht C, Thorstensson R, Thalen M, Lore K. Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans. J Clin Invest. 2020 May 1;130(5):2332-2346. doi: 10.1172/JCI135020.'},\n",
       "      {'pmid': '26057135',\n",
       "       'type': 'DERIVED',\n",
       "       'citation': 'Carlsson RM, Gustafsson L, Hallander HO, Ljungman M, Olin P, Gothefors L, Nilsson L, Netterlid E. Two consecutive randomized controlled pertussis booster trials in children initially vaccinated in infancy with an acellular vaccine: The first with a five-component Tdap vaccine to 5-year olds and the second with five- or monocomponent Tdap vaccines at age 14-15 years. Vaccine. 2015 Jul 17;33(31):3717-25. doi: 10.1016/j.vaccine.2015.05.079. Epub 2015 Jun 7.'},\n",
       "      {'pmid': '25008903',\n",
       "       'type': 'DERIVED',\n",
       "       'citation': 'Jahnmatz M, Ljungman M, Netterlid E, Jenmalm MC, Nilsson L, Thorstensson R. Pertussis-specific memory B-cell and humoral IgG responses in adolescents after a fifth consecutive dose of acellular pertussis vaccine. Clin Vaccine Immunol. 2014 Sep;21(9):1301-8. doi: 10.1128/CVI.00280-14. Epub 2014 Jul 9.'}]}},\n",
       "   'derivedSection': {'miscInfoModule': {'versionHolder': '2024-08-26'},\n",
       "    'conditionBrowseModule': {'meshes': [{'id': 'D000014917',\n",
       "       'term': 'Whooping Cough'},\n",
       "      {'id': 'D000013742', 'term': 'Tetanus'},\n",
       "      {'id': 'D000004165', 'term': 'Diphtheria'},\n",
       "      {'id': 'D000013746', 'term': 'Tetany'}],\n",
       "     'ancestors': [{'id': 'D000001885', 'term': 'Bordetella Infections'},\n",
       "      {'id': 'D000016905', 'term': 'Gram-Negative Bacterial Infections'},\n",
       "      {'id': 'D000001424', 'term': 'Bacterial Infections'},\n",
       "      {'id': 'D000001423', 'term': 'Bacterial Infections and Mycoses'},\n",
       "      {'id': 'D000007239', 'term': 'Infections'},\n",
       "      {'id': 'D000012141', 'term': 'Respiratory Tract Infections'},\n",
       "      {'id': 'D000012140', 'term': 'Respiratory Tract Diseases'},\n",
       "      {'id': 'D000003015', 'term': 'Clostridium Infections'},\n",
       "      {'id': 'D000016908', 'term': 'Gram-Positive Bacterial Infections'},\n",
       "      {'id': 'D000020879', 'term': 'Neuromuscular Manifestations'},\n",
       "      {'id': 'D000009461', 'term': 'Neurologic Manifestations'},\n",
       "      {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "      {'id': 'D000006996', 'term': 'Hypocalcemia'},\n",
       "      {'id': 'D000002128', 'term': 'Calcium Metabolism Disorders'},\n",
       "      {'id': 'D000008659', 'term': 'Metabolic Diseases'},\n",
       "      {'id': 'D000003354', 'term': 'Corynebacterium Infections'},\n",
       "      {'id': 'D000000193', 'term': 'Actinomycetales Infections'}],\n",
       "     'browseLeaves': [{'id': 'M17656',\n",
       "       'name': 'Whooping Cough',\n",
       "       'asFound': 'Pertussis',\n",
       "       'relevance': 'HIGH'},\n",
       "      {'id': 'M7347',\n",
       "       'name': 'Diphtheria',\n",
       "       'asFound': 'Diphtheria',\n",
       "       'relevance': 'HIGH'},\n",
       "      {'id': 'M16511',\n",
       "       'name': 'Tetanus',\n",
       "       'asFound': 'Tetanus',\n",
       "       'relevance': 'HIGH'},\n",
       "      {'id': 'M16515',\n",
       "       'name': 'Tetany',\n",
       "       'asFound': 'Tetanus',\n",
       "       'relevance': 'HIGH'},\n",
       "      {'id': 'M6590', 'name': 'Cough', 'relevance': 'LOW'},\n",
       "      {'id': 'M10283', 'name': 'Infections', 'relevance': 'LOW'},\n",
       "      {'id': 'M6368', 'name': 'Communicable Diseases', 'relevance': 'LOW'},\n",
       "      {'id': 'M5163', 'name': 'Bordetella Infections', 'relevance': 'LOW'},\n",
       "      {'id': 'M4722', 'name': 'Bacterial Infections', 'relevance': 'LOW'},\n",
       "      {'id': 'M19249',\n",
       "       'name': 'Gram-Negative Bacterial Infections',\n",
       "       'relevance': 'LOW'},\n",
       "      {'id': 'M12136', 'name': 'Mycoses', 'relevance': 'LOW'},\n",
       "      {'id': 'M4721',\n",
       "       'name': 'Bacterial Infections and Mycoses',\n",
       "       'relevance': 'LOW'},\n",
       "      {'id': 'M14978',\n",
       "       'name': 'Respiratory Tract Infections',\n",
       "       'relevance': 'LOW'},\n",
       "      {'id': 'M14977',\n",
       "       'name': 'Respiratory Tract Diseases',\n",
       "       'relevance': 'LOW'},\n",
       "      {'id': 'M6247', 'name': 'Clostridium Infections', 'relevance': 'LOW'},\n",
       "      {'id': 'M19252',\n",
       "       'name': 'Gram-Positive Bacterial Infections',\n",
       "       'relevance': 'LOW'},\n",
       "      {'id': 'M22619',\n",
       "       'name': 'Neuromuscular Manifestations',\n",
       "       'relevance': 'LOW'},\n",
       "      {'id': 'M12404',\n",
       "       'name': 'Neurologic Manifestations',\n",
       "       'relevance': 'LOW'},\n",
       "      {'id': 'M10046', 'name': 'Hypocalcemia', 'relevance': 'LOW'},\n",
       "      {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'},\n",
       "      {'id': 'M5391',\n",
       "       'name': 'Calcium Metabolism Disorders',\n",
       "       'relevance': 'LOW'},\n",
       "      {'id': 'M6574',\n",
       "       'name': 'Corynebacterium Infections',\n",
       "       'relevance': 'LOW'},\n",
       "      {'id': 'T5926',\n",
       "       'name': 'Whooping Cough',\n",
       "       'asFound': 'Pertussis',\n",
       "       'relevance': 'HIGH'},\n",
       "      {'id': 'T1885',\n",
       "       'name': 'Diphtheria',\n",
       "       'asFound': 'Diphtheria',\n",
       "       'relevance': 'HIGH'},\n",
       "      {'id': 'T5607',\n",
       "       'name': 'Tetanus',\n",
       "       'asFound': 'Tetanus',\n",
       "       'relevance': 'HIGH'}],\n",
       "     'browseBranches': [{'abbrev': 'BC01', 'name': 'Infections'},\n",
       "      {'abbrev': 'BC08',\n",
       "       'name': 'Respiratory Tract (Lung and Bronchial) Diseases'},\n",
       "      {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "      {'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "      {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'},\n",
       "      {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "      {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "    'interventionBrowseModule': {'browseLeaves': [{'id': 'M17360',\n",
       "       'name': 'Vaccines',\n",
       "       'relevance': 'LOW'}],\n",
       "     'browseBranches': [{'abbrev': 'All',\n",
       "       'name': 'All Drugs and Chemicals'}]}},\n",
       "   'hasResults': False}]}"
      ]
     },
     "execution_count": 83,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# test get by search condition FHA\n",
    "cond = 'FHA'\n",
    "\n",
    "# curl -X GET \"https://clinicaltrials.gov/api/v2/studies?query.cond=FHA\" -H \"accept: application/json\" \n",
    "get_by_cond_endpoint = f\"{API_SERVER}/studies?query.cond={cond}\"\n",
    "\n",
    "resp_cond = requests.get(get_by_cond_endpoint).json()\n",
    "resp_cond"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "5"
      ]
     },
     "execution_count": 86,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(resp['studies'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "    params = {\n",
    "        \"query.cond\": \"FHA\",\n",
    "        \"pageSize\": 20,\n",
    "#        \"query.titles\":\n",
    "    }"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Part 3 - API payload schema parsing sandbox - parse those criteria into some structured format"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# parse those criteria into some structured format: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10797270/ \n",
    "\n",
    "# OMOP format: https://www.ohdsi.org/data-standardization/ "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# https://github.com/OHDSI/"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.18"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 1
}
